- Outcomes of Intra-Arterial Tenecteplase after Endovascular Reperfusion for Acute Ischemic Stroke Due to Cardioembolism and Non-Cardioembolism: A Secondary Analysis of the POST-TNK Trial. [Journal Article]Ann Neurol. 2026 Aug 07. [Online ahead of print]AN
- CONCLUSIONS: In patients with AIS due to CE who achieved near-complete to complete reperfusion after EVT, adjunctive intra-arterial TNK was associated with a higher likelihood of freedom from disability at 90 days, without increasing the risk of mortality or ICH. However, this benefit was not observed in AIS patients due to non-CE. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- A Human Gait Circuit Derived from Brain Lesions and Deep Brain Stimulation. [Journal Article]Ann Neurol. 2026 Aug 06. [Online ahead of print]AN
- CONCLUSIONS: Lesion locations impairing gait and DBS sites modulating gait converge on a common brain circuit. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Genetic Modifiers of ABCA1 Activity Interact with APOE Isoforms to Mediate Alzheimer's Disease Risk. [Journal Article]Ann Neurol. 2026 Aug 03. [Online ahead of print]AN
- CONCLUSIONS: Genetic modifiers of ABCA1 activity interact with APOE isoforms to alter AD risk. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3. [Journal Article]Ann Neurol. 2026 Jul 31. [Online ahead of print]AN
- CONCLUSIONS: These findings define a pathogenic role for repeat expansion-driven peripheral nerve degeneration in SCA3, identify sensory neurons as key therapeutic targets, and provide a preclinical platform for developing peripheral interventions in SCA3 and related repeat expansion disorders. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial. [Journal Article]Ann Neurol. 2026 Jul 30. [Online ahead of print]AN
- CONCLUSIONS: Ocrelizumab treatment controlled disease activity in black and Hispanic people with relapsing multiple sclerosis. Results were consistent with pivotal ocrelizumab trials, supporting ocrelizumab's effectiveness and tolerability in these populations. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Toward a Behavioral Reserve Model in Amyotrophic Lateral Sclerosis. [Journal Article]Ann Neurol. 2026 Jul 30. [Online ahead of print]AN
- CONCLUSIONS: These findings provide empirical support for a behavioral reserve framework in ALS, in which premorbid regulatory traits and socio-educational exposures are associated with behavioral vulnerability. Although causal inference is limited, reserve-related factors may contribute to non-motor heterogeneity in ALS and may inform future approaches to early behavioral risk stratification. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Facial Weakness Revealing Rare Familial Polyneuropathy. [Journal Article]Ann Neurol. 2026 Jul 30. [Online ahead of print]AN
- Publisher Full Text (DOI)
- Blood Biomarkers of Alzheimer's Disease and Patterns of Structural Brain Changes in the Community. [Journal Article]Ann Neurol. 2026 Jul 27. [Online ahead of print]AN
- CONCLUSIONS: In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation. These findings suggest that AD-related blood biomarkers may capture different dementia-related structural brain changes already at early stages. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Outcomes of Bilateral Globus Pallidus Internus Deep Brain Stimulation in GNAO1-Related Disorder: An International Multicenter Experience. [Journal Article]Ann Neurol. 2026 Jul 27. [Online ahead of print]AN
- CONCLUSIONS: Bilateral GPi-DBS was associated with sustained prevention of dyskinetic crises and reduction of overall disease burden in GNAO1-related disorder, with limited impact on functional classification. These findings support earlier elective neuromodulation before recurrent crises drive cumulative morbidity and identify GPi-DBS as a crisis-preventive, symptom-modifying intervention rather than a restorative one. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Regional and Compartmental Changes Drive Progressive Patterns of Striatal Degeneration in X-Linked Dystonia Parkinsonism. [Journal Article]Ann Neurol. 2026 Jul 26. [Online ahead of print]AN
- CONCLUSIONS: Our findings provide a novel perspective on the pattern and degree of degeneration of the XDP striatum. We propose that the matrix compartment is more vulnerable to disease impact relative to striosomes than initially thought, and the pattern of striatal degeneration may be indicative of the breakdown of a wider cortico-basal ganglia neural circuit over the duration of the disease. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Age Is an Effect Modifier of Thrombectomy Benefit in a Socioeconomically Vulnerable Stroke Population. [Journal Article]Ann Neurol. 2026 Jul 24. [Online ahead of print]AN
- CONCLUSIONS: The effect of EVT appears significantly diminished among elderly patients in a public healthcare system in a developing country. Further studies are needed to understand the mechanism underlying these findings and properly assess the efficacy of EVT in this vulnerable population. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Neurotransmitter-Defined Degeneration Patterns in Sporadic and C9orf72-Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems-Implications for Therapy Development. [Journal Article]Ann Neurol. 2026 Jul 21. [Online ahead of print]AN
- CONCLUSIONS: Our data suggest the preferential vulnerability of GABAergic, serotonergic, kappa opioid mediated networks in sporadic ALS. In C9orf72-assocaited ALS, glutamatergic, endocannabinoid circuits are also susceptible and microglia-mediated neuroinflammation is also implicated. The comprehensive evaluation of neurotransmitter-receptor associations not only offer academic insights regarding pathophysiological processes in ALS, but may inform targeted therapy development strategies. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- The Case for Master Protocols for Rare Neurological Diseases. [Journal Article]Ann Neurol. 2026 Jul 21. [Online ahead of print]AN
- Master protocol trials allow for simultaneous multiple hypothesis testing within a common framework and might be applicable for rare diseases. In May 2025, the Network for Excellence in Neuroscience Clinical Trials convened a multistakeholder conference to discuss master protocol trials in rare neurological disorders. In this paper, we explore how master protocol trial designs may apply to rare n…
- Publisher Full Text (DOI)
- Monitoring Antiseizure Medication Change Using Ultra Long-Term Electroencephalogram: A Multicenter Study. [Journal Article]Ann Neurol. 2026 Jul 20. [Online ahead of print]AN
- CONCLUSIONS: SqEEG detects more seizures than patient-reported diaries and identifies treatment-related changes earlier, even after modest medication adjustments, particularly after dose reductions, highlighting the potential of objective ultra long-term EEG monitoring in treatment-resistant epilepsy. ANN NEUROL 2026.
- Publisher Full Text (DOI)
- Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System. [Journal Article]
- CONCLUSIONS: Big tau represents a distinct tau population enriched in the PNS and uncoupled from disease-associated changes in brain-derived tau, suggesting that distinguishing big tau from canonical tau may improve interpretation of tau biomarkers and help differentiate CNS neurodegeneration from peripheral nerve pathology. ANN NEUROL 2026.
- Publisher Full Text (DOI)